10-Q: Astrotech Corp Reports Increased Revenue in Q2 2024, Driven by TRACER 1000 Sales

Astrotech Corporation saw a significant increase in revenue during the second quarter of fiscal year 2024, primarily due to sales of its TRACER 1000 explosives trace detectors.

Summary

• Astrotech Corporation's revenue increased to $1.115 million in the three months ended December 31, 2023, compared to $263 thousand in the same period of 2022.
• The company's gross profit for the quarter was $532 thousand, up from $108 thousand in the prior year.
• Operating expenses totaled $3.6 million, an increase from $2.922 million in the prior year.
• The net loss for the quarter was $2.641 million, compared to a net loss of $2.418 million in the same period of 2022.
• For the six months ended December 31, 2023, revenue was $1.540 million, compared to $301 thousand in the same period of 2022.
• The net loss for the six months ended December 31, 2023, was $5.553 million, compared to a net loss of $4.947 million in the same period of 2022.
• The company's cash and cash equivalents decreased to $11.096 million as of December 31, 2023, from $14.208 million as of June 30, 2023.
• The company has deployed the TRACER 1000 in approximately 29 locations in 14 countries throughout Europe and Asia.
• AgLAB's field trials showed an average of 30% improvement in ending-weights yields using the AgLAB 1000-D2 mass spectrometer.

Sentiment

Score: 6

Explanation: The document shows positive revenue growth and progress in product development, but the company is still operating at a loss and faces challenges in obtaining regulatory approvals. The sentiment is cautiously optimistic.

Positives

• Revenue increased significantly due to sales of the TRACER 1000.
• Gross profit improved substantially compared to the same period last year.
• AgLAB's field trials showed a significant improvement in yields using their technology.
• The company has successfully deployed the TRACER 1000 in multiple international locations.
• The company is seeing increased income from short-term investments due to higher interest rates.

Negatives

• The company continues to operate at a net loss.
• Operating expenses have increased, driven by sales and R&D activities.
• Cash and cash equivalents have decreased during the period.
• The company is still awaiting TSA certification for the TRACER 1000 in the US.

Risks

• The company is subject to various lawsuits and other claims in the normal course of business.
• The company is dependent on a limited number of customers for a material portion of its revenue.
• The company's cash balances may exceed the limit insured by the FDIC.
• The company is subject to risks related to the availability of, and cost inflation in, supply chain inputs.
• The company is subject to uncertainty in government funding and support for key programs.
• The company is subject to the impact of competition on its ability to win new contracts.
• The company is subject to the risk of not meeting technological development milestones and overcoming development challenges.
• The company is subject to the risk of not successfully identifying, completing and integrating acquisitions.
• The company may be detrimentally affected by a change in enforcement by federal or state governments regarding cannabis and hemp.

Future Outlook

The company is focused on commercializing its mass spectrometry technology through its subsidiaries and is working towards TSA certification for the TRACER 1000 in the US. The company believes it will be able to pass the inflation caused by raw materials shortages and increased shipping costs to its customers by increasing the price of its instruments.

Management Comments

• Management believes the AgLAB 1000-D2 will deliver a compelling combination of cost and time savings while enhancing product quality and quantity for distillation processors of hemp and cannabis.
• Management believes the AMS Technology provides a significant competitive advantage due to its small size, rugged design, quick analysis, and ease of use.
• Management believes that new tools to more quickly identify an infection may be present remain of the utmost importance in the battle against COVID-19 and other diseases.

Industry Context

The company operates in the mass spectrometry, security, agriculture, and healthcare industries. The company's technology is positioned to disrupt traditional methods in these sectors. The company is leveraging its core technology across multiple applications, which is a common strategy for technology companies with broad potential.

Comparison to Industry Standards

• The TRACER 1000 is positioned as a superior alternative to ion mobility spectrometry (IMS)-based explosives trace detectors, which are commonly used in airport security.
• AgLAB's mass spectrometry technology is presented as a more efficient and effective solution for hemp and cannabis processing compared to high-performance liquid chromatography (HPLC).
• The company's focus on real-time analysis and process control aligns with industry trends towards automation and efficiency in manufacturing and agriculture.
• The company's breath analysis technology is aimed at addressing the need for rapid and accurate disease detection, which is a growing area of interest in the healthcare industry.

Corporate Governance

Legal Proceedings

• The company is subject to various lawsuits and other claims in the normal course of business, but management does not believe any matters will have a material adverse effect on the company's financial position or results of operations.

Stakeholder Impact

• Shareholders may be impacted by the company's continued net losses and the potential for dilution.
• Employees may be impacted by the company's financial performance and any changes in operations.
• Customers may benefit from the company's innovative products and services.
• Suppliers may be impacted by the company's financial performance and any changes in purchasing patterns.
• Creditors may be impacted by the company's financial performance and ability to repay debts.

Next Steps

• The company will continue to work towards TSA certification for the TRACER 1000.
• The company will continue to develop and commercialize its mass spectrometry technology across its subsidiaries.
• The company will continue to conduct field trials for AgLAB products.
• The company will continue to develop the BreathTest-1000 for disease screening.

Key Dates

Keywords

mass spectrometry, explosives detection, TRACER 1000, AgLAB, hemp, cannabis, breath analysis, BreathTech, process control, chemical manufacturing, TSA, ECAC, revenue, net loss, R&D